Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.08.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Xin Luo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States of America; Department of Bioengineering, Ric…. Hauptthemen laut MEDLINE: Extracellular Vesicles, COVID-19 Vaccines, Cancer Vaccines, RNA, Messenger. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
mRNA incorporated in lipid nanoparticles (LNPs) became a new class of vaccine modality for induction of immunity against COVID-19 and ushered in a new era in vaccine development. Here, we report a novel, easy-to-execute, and cost effective engineered extracellular vesicles (EVs)-based combined mRNA and protein vaccine platform (EVX-M+P vaccine) and explore its utility in proof-of-concept immunity studies in the settings of cancer and infectious disease. As a first example, we engineered EVs, natural nanoparticle carriers shed by all cells, to contain ovalbumin mRNA and protein (EVOvaM+P vaccine) to serve as cancer vaccine against ovalbumin-expressing melanoma tumors. EVOvaM+P administration to mice with established melanoma tumors resulted in tumor regression associated with effective humoral and adaptive immune responses. As a second example, we generated engineered EVs that contain Spike (S) mRNA and protein to serve as a combined mRNA and protein vaccine (EVSpikeM+P vaccine) against SARS-CoV-2 infection. EVSpikeM+P vaccine administration in mice and baboons elicited robust production of neutralizing IgG antibodies against RBD (receptor binding domain) of S protein and S protein specific T cell responses. Our proof-of-concept study describes a new platform with an ability for rapid development of combination mRNA and protein vaccines employing EVs for deployment against cancer and other diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States of America; Department of Bioengineering, Rice University, Houston, TX, United States of America.
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
- Michale E. Keeling Center for Comparative Medicine and Research, University of Texas MD Anderson Cancer Center, Bastrop, TX, United States of America.
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States of America; Department of Internal Medicine, Baylor College of Medicine, Houston, TX, United States of America.
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States of America; Department of Bioengineering, Rice University, Houston, TX, United States of America; Department of Mol…
Förderung
- NCI NIH HHS
- NIH HHS
Zitieren
APA
Luo, X., McAndrews, K. M., Arian, K. A., Morse, S. J., Boeker, V., Kumbhar, S. V., Hu, Y., Mahadevan, K. K., Church, K. A., Chitta, S., Ryujin, N. T., Hensel, J., Dai, J., Dowlatshahi, D. P., Sugimoto, H., Kirtley, M. L., LeBleu, V. S., Shalapour, S., Simmons, J. H., & Kalluri, R. (2024). Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.08.017
Vancouver
Luo X, McAndrews KM, Arian KA, Morse SJ, Boeker V, Kumbhar SV, et al. Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.08.017
BibTeX
@article{Luo2024,
author = {Luo, Xin and McAndrews, Kathleen M and Arian, Kent A and Morse, Sami J and Boeker, Viktoria and Kumbhar, Shreyasee V and Hu, Yingying and Mahadevan, Krishnan K and Church, Kaira A and Chitta, Sriram and Ryujin, Nicolas T and Hensel, Janine and Dai, Jianli and Dowlatshahi, Dara P and Sugimoto, Hikaru and Kirtley, Michelle L and LeBleu, Valerie S and Shalapour, Shabnam and Simmons, Joe H and Kalluri, Raghu},
title = {Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.08.017}
}
EUVIMED